Karyopharm Therapeutics Inc (KPTI : NASDAQ)
Common Stock
$0.83
USD
+0.35 (73.35%)
Last updated: 2026-10-28
Follow KPTI
KPTI
Karyopharm Therapeutics Inc
WealthAwesomePerformance
1 Day
+73.35%
1 Week
+96.07%
1 Month
-48.64%
YTD
-91.15%
Key Statistics
Market Cap
$18.87M
52W High
$10.99
52W Low
$0.31
P/E Ratio
-
50 Day MA
$1.27
200 Day MA
$6.10
Beta
1.04
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/28/2026 | $0.46 | $0.91 | $0.46 | $0.83 | $0.83 | 52,782,079 |
| 10/27/2026 | $0.46 | $0.48 | $0.43 | $0.48 | $0.48 | 996,614 |
| 10/26/2026 | $0.51 | $0.52 | $0.42 | $0.48 | $0.48 | 1,363,766 |
| 10/23/2026 | $0.54 | $0.56 | $0.44 | $0.52 | $0.52 | 1,959,000 |
| 10/22/2026 | $0.44 | $0.55 | $0.42 | $0.55 | $0.55 | 7,287,547 |
| 10/21/2026 | $0.36 | $0.44 | $0.36 | $0.42 | $0.42 | 1,538,271 |
| 10/20/2026 | $0.34 | $0.39 | $0.34 | $0.36 | $0.36 | 761,154 |
| 10/19/2026 | $0.40 | $0.40 | $0.33 | $0.35 | $0.35 | 1,247,202 |
| 10/16/2026 | $0.35 | $0.40 | $0.33 | $0.39 | $0.39 | 2,707,000 |
| 10/15/2026 | $0.31 | $0.35 | $0.31 | $0.35 | $0.35 | 1,321,959 |
Analyst Price Targets
Based on 5 analysts covering KPTI · as of Oct 5, 2026
Wall Street analysts forecast KPTI stock price to rise 771.3% over the next 12 months.
Consensus
Buy4.20 / 5.00
Avg. Target
US$7.25
+771.3% Upside
Current Price
US$0.83
Last close
Analyst Breakdown (5 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on KPTI's historical volatility
30-Day Vol
269.9%
Annualized
90-Day Vol
276.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$0.70
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$0.78 | US$0.31 – US$1.99 |
| 60 trading days | US$0.74 | US$0.20 – US$2.76 |
| 90 trading days | US$0.70 | US$0.14 – US$3.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Financials
- Revenue (TTM)
- $146.62M
- EBITDA
- $-82.20M
- Profit Margin
- -153.28%
- ROE (TTM)
- -891.05%
- EPS (Diluted)
- -14.33
- Book Value
- -14.56
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About KPTI.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| AXG | Solowin Holdings | $5.68 | +14100.00% |
| ATYR | aTyr Pharma, Inc. | $5.14 | +4041.94% |
| OMEX | Odyssey Marine Exploration Inc | $13.55 | +2418.59% |
| HVII | Hennessy Capital Investment Corp. VII Ordinary Shares | $4.46 | +243.08% |
| ULBI | Ultralife Corporation | $15.61 | +145.44% |
| ATII | Archimedes Tech SPAC Partners II Co. Ordinary Shares | $9.81 | +110.06% |
| RITRF | Reitar Logtech Holdings Limited | $0.02 | +86.09% |
| FTFT | Future Fintech Group Inc | $2.89 | +55.38% |